



FOR IMMEDIATE RELEASE

First Patient Enrolled in Pique Therapeutics Phase 2 Clinical Trial of PT 107 in Non-Small Cell Lung Cancer

Durham, North Carolina – March 9, 2011 -- Pique Therapeutics, Inc. announced today that the first patient has been enrolled in the Phase 2 clinical trial of its lead program, PT 107, for the treatment of non-small cell lung cancer.

The Phase 2 program is a randomized double-blind, placebo-controlled clinical trial, enrolling 100 patients with Stage IIIB/IV non-small cell lung cancer who have failed previous therapy. The Phase 2 trial seeks to confirm the safety of PT 107, and further evaluate the efficacy of the drug. Overall survival is the primary endpoint, and interim results from the trial are expected in early 2012.

Pique previously announced a strategic partnership with Technomark Life Sciences to conduct the Phase 2 program, where Pique maintains exclusive rights to PT 107 in major global markets, including the United States, Europe, and Japan, while Technomark has exclusive rights to PT 107 in selected emerging markets, such as India and China.

About Pique Therapeutics

Pique Therapeutics is a biopharmaceutical company seeking to become the leader in the development and commercialization of new therapeutic vaccines, focused initially on the treatment of cancer. The Company was founded on the research of Eckhard R. Podack, M.D., Ph.D., who is Chair of the Department of Immunology and Microbiology at the University of Miami.

About PT 107

Pique's lead product, PT 107, is a first-in-class therapeutic vaccine for the treatment of non-small cell lung cancer and has completed Phase 1 clinical trials, where it was well tolerated, and exhibited a very good safety profile in cancer patients. PT 107 showed a dramatic improvement in median overall survival (11 months) for patients with second-line, late-stage non-small cell lung cancer, more than doubling the expected 4 to 6 months survival in these patients. Remarkably, over 30% of PT 107-treated patients survived 4 years or longer, while currently-approved treatments extend overall survival in this group of patients by approximately 2-3 months. PT 107 is also being studied in a two-arm, double-blind Phase 2 clinical trial in the United States.

Contact:

Christopher S. Meldrum

President

Pique Therapeutics, Inc.

(919) 806-4395